Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates

Core Insights - Protagonist Therapeutics reported a quarterly loss of $0.62 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.59, and compared to a loss of $0.54 per share a year ago, indicating a negative earnings surprise of -5.08% [1] - The company generated revenues of $4.71 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 52.88%, and showing a slight increase from $4.68 million in the same quarter last year [2] - Protagonist Therapeutics shares have increased approximately 101.8% year-to-date, significantly outperforming the S&P 500's gain of 15.6% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.53 on revenues of $10.35 million, and for the current fiscal year, it is -$1.84 on revenues of $50.25 million [7] - The estimate revisions trend for Protagonist Therapeutics was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Protagonist Therapeutics belongs, is currently ranked in the top 41% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Another company in the same industry, ADC Therapeutics SA, is expected to report a quarterly loss of $0.40 per share, with revenues projected at $16.1 million, down 12.8% from the previous year [9][10]